RESUMO
BACKGROUND: The combination of probiotics and prebiotics might be useful to treat oral halitosis. The aim of this study was to assess the effect of Lactobacillus salivarius G60 (LS) and inulin on oral halitosis and tongue coating. METHODS: In this double-masked, randomized, phase II clinical trial, 45 patients (aged 35 ± 15 years, 66% female) with oral halitosis and tongue coating were allocated to three treatment groups (n = 15) using gums of oral dissolution (one gum every 12 hours) for 10 days. Each gum contained LS (1 billion colony forming units [CFUs]) + inulin (1 g), LS (1 billion CFU) or placebo. Primary outcomes were organoleptic test, Halimeter, and tongue coating, whereas secondary outcomes were quality of life (QOL) and treatment safety. Generalized linear models were used, adjusting for age and sex. In vitro tests were performed to verify whether LS interacts with inulin and whether LS inhibits the growth of Porphyromonas gingivalis and Prevotella intermedia. RESULTS: Forty-four patients (97%) completed the study. Patients treated with LS + inulin showed greater reduction in halitosis measured by Halimeter compared with placebo (adjusted post-intervention average: 96.7 versus 142.5 ppb; P = 0.003), whereas LS and placebo did not differ (115.7 versus 142.5 ppb; P = 0.097). Organoleptic measurements and coating index showed a similar decrease for all groups. QOL improved in patients treated with LS + inulin compared with placebo (P = 0.029). Side effects were mild and transient in all groups. LS did not metabolize inulin but inhibited the growth of P. gingivalis and P. intermedia after 72 hours. CONCLUSIONS: Treatment with L. salivarius G60 combined or not with inulin showed significant decrease in the outcomes organoleptic test, Halimeter, and coating index, improving oral halitosis. However, no significant difference was obtained between the groups.
Assuntos
Halitose , Ligilactobacillus salivarius , Probióticos , Adulto , Feminino , Halitose/tratamento farmacológico , Humanos , Inulina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Probióticos/uso terapêutico , Qualidade de Vida , Adulto JovemRESUMO
INTRODUCTION: Breast cancer is the most frequently diagnosed malignancy in women, and comorbidities like hypertension and obesity diminish their quality of life and negatively affect their response to chemotherapy. Furthermore, inulin supplementation is associated with the reduction of cardiovascular diseases (CVD) risk. OBJECTIVE: To determine whether inulin supplementation prevents the elevation of blood pressure in women with breast cancer undergoing neoadjuvant therapy with cyclophosphamide and doxorubicin. METHODS: This was a randomized, double-blind placebo controlled trial which included women with early-stage breast cancer undergoing neoadjuvant therapy (n=38). Patients were randomly assigned to participate in two different groups to receive either 15 g of inulin or 15 g of placebo (maltodextrin) for 21 days. Body composition and blood pressure were evaluated before and after the supplementation period. RESULTS: Women in the inulin group showed a lower systolic blood pressure (SBP) after the supplementation (-4.21 mmHg, p<0.001). However, SBP increased in the placebo supplemented group. Diastolic blood pressure (DBP) nonsignificantly decreased in the inulin group. Inulin supplementation also increased BMI (p<0.001) but reduced BFP (p=0.288). Furthermore, confounding variables, such as BMI, baseline fasting glucose, age, menopause status, vomiting, constipation, and chronic medication did not have a statistical influence over the inulin effect on SBP. CONCLUSION: Inulin supplementation reduces SBP and prevents increases in DBP in women with breast cancer. This could be an innovative nutraceutical approach to prevent hypertension present in women with this type of cancer at an early stage and may improve the quality of life of the patients and their prognostic development through chemotherapy. TRIAL REGISTRATION NUMBER: This trial is registered with ACTRN12616001532493.
Assuntos
Anti-Hipertensivos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Neoplasias da Mama/tratamento farmacológico , Hipertensão/prevenção & controle , Inulina/uso terapêutico , Terapia Neoadjuvante , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Comorbidade , Ciclofosfamida/administração & dosagem , Método Duplo-Cego , Doxorrubicina/administração & dosagem , Feminino , Humanos , Hipertensão/epidemiologia , Hipertensão/fisiopatologia , Inulina/efeitos adversos , México/epidemiologia , Pessoa de Meia-Idade , Terapia Neoadjuvante/efeitos adversos , Estadiamento de Neoplasias , Fatores de Risco , Fatores de Tempo , Resultado do TratamentoRESUMO
Annual mortality rates due to infectious diarrhea are about 2.2 million; children are the most vulnerable age group to severe gastroenteritis, representing group A rotaviruses as the main cause of disease. One of the main factors of rotavirus pathogenesis is the NSP4 protein, which has been characterized as a viral toxin involved in triggering several cellular responses leading to diarrhea. Furthermore, the rotavirus protein NSP1 has been associated with interferon production inhibition by inducing the degradation of interferon regulatory factors IRF3, IRF5, and IRF7. On the other hand, probiotics such as Bifidobacterium and Lactobacillus species in combination with prebiotics such as inulin, HMO, scGOS, lcFOS have been associated with improved generalized antiviral response and anti-rotavirus effect by the reduction of rotavirus infectivity and viral shedding, decreased expression of NSP4 and increased levels of specific anti-rotavirus IgAs. Moreover, these probiotics and prebiotics have been related to shorter duration and severity of rotavirus diarrhea, to the prevention of infection and reduced incidence of reinfections. In this review we will discuss in detail about the rotavirus pathogenesis and immunity, and how probiotics such as Lactobacillus and Bifidobacterium species in combination with prebiotics have been associated with the prevention or modulation of rotavirus severe gastroenteritis.
Assuntos
Antivirais/uso terapêutico , Bifidobacterium/fisiologia , Gastroenterite/terapia , Lactobacillus/fisiologia , Prebióticos/estatística & dados numéricos , Probióticos/uso terapêutico , Infecções por Rotavirus/terapia , Rotavirus/efeitos dos fármacos , Criança , Diarreia/terapia , Diarreia/virologia , Feminino , Gastroenterite/virologia , Glicoproteínas/metabolismo , Humanos , Lactente , Inulina/uso terapêutico , Rotavirus/imunologia , Toxinas Biológicas/metabolismo , Proteínas não Estruturais Virais/metabolismoRESUMO
INTRODUCTION: Mixed dyslipidemia accelerates atherosclerosis and leads to cardiovascular disease and death. Non-soluble fibers such as inulin have been shown to have an effect on dyslipidemia. AIM: To assess the effect of the combination of simvastatin plus inulin in comparison with simvastatin plus ezetimibe in mixed dyslipidemia. MATERIAL AND METHODS: A randomized, double-blind, clinical trial with parallel control group was performed in 60 patients with mixed dyslipidemia, without drug treatment or failure to statins and lifestyle changes. INTERVENTION: simvastatin (20 mg), inulin from agave (7 g) and placebo of ezetimibe, or simvastatin (20 mg), ezetimibe (10 mg) and placebo of inulin from agave, daily at night, for 12 weeks. RESULTS: Both groups decreased total cholesterol (235 ± 29 vs. 182 ± 42 mg/dl; p = 0.001 and 236 ± 31 vs. 160 ± 48 mg/dl; p < 0.001), low-density lipoprotein cholesterol (141 ± 32 vs. 99 ± 34 mg/dl; p < 0.001 and 149 ± 35 vs. 89 ± 43 mg/dl; p < 0.001) and triglycerides (284 ± 117 vs. 214 ± 137 mg/dl; p = 0.027 and 241 ± 81 vs. 180 ± 68 mg/dl; p < 0.001), respectively, for simvastatin plus inulin and simvastatin plus ezetimibe. CONCLUSION: The combination of simvastatin plus inulin reduced total cholesterol, low-density lipoprotein cholesterol, and triglycerides the same as simvastatin plus ezetimibe.
Assuntos
Anticolesterolemiantes/uso terapêutico , Dislipidemias/tratamento farmacológico , Ezetimiba/uso terapêutico , Inulina/uso terapêutico , Sinvastatina/uso terapêutico , Adulto , LDL-Colesterol , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
Prebiotics may increase intestinal Fe absorption in anaemic growing rats. The present study evaluated the effects of high-performance (HP) inulin and oligofructose on factors that regulate Fe absorption in anaemic rats during the growth phase. Male Wistar rats aged 21 d of age were fed AIN-93G ration without Fe for 2 weeks to induce Fe-deficiency anaemia. The rats were fed on day 35 a control diet, or a diet with 10 % HP inulin, or a diet with 10 % oligofructose, without Fe supplementation. The animals were euthanised after 2 weeks, and segments of the duodenum, caecum, colon and liver were removed. The expression levels of proteins in the intestinal segments were assessed using Western blotting. The levels of serum, urine and liver hepcidin and the concentrations of IL-10, IL-6 and TNF-α in the caecum, colon and liver were measured using the ELISA test. HP inulin increased the expression of the divalent metal transporter 1 protein in the caecum by 162 % (P= 0·04), and the expression of duodenal cytochrome b reductase in the colon by 136 % (P= 0·02). Oligofructose decreased the expression of the protein ferroportin in the duodenum (P= 0·02), the concentrations of IL-10 (P= 0·044), IL-6 (P= 0·036) and TNF-α (P= 0·004) in the caecum, as well as the level of urinary hepcidin (P< 0·001). These results indicate that prebiotics may interfere with the expression of various intestinal proteins and systemic factors involved in the regulation of intestinal Fe absorption in anaemic rats during the growth phase.
Assuntos
Anemia Ferropriva/dietoterapia , Proteínas de Transporte de Cátions/metabolismo , Grupo dos Citocromos b/metabolismo , Mucosa Intestinal/metabolismo , Prebióticos , Regulação para Cima , Anemia Ferropriva/imunologia , Anemia Ferropriva/metabolismo , Anemia Ferropriva/patologia , Animais , Proteínas de Transporte de Cátions/agonistas , Ceco/imunologia , Ceco/metabolismo , Ceco/patologia , Colo/enzimologia , Colo/imunologia , Colo/metabolismo , Grupo dos Citocromos b/química , Grupo dos Citocromos b/genética , Duodeno/imunologia , Duodeno/metabolismo , Duodeno/patologia , Hepcidinas/sangue , Hepcidinas/metabolismo , Hepcidinas/urina , Mediadores da Inflamação/metabolismo , Mucosa Intestinal/imunologia , Mucosa Intestinal/patologia , Inulina/efeitos adversos , Inulina/uso terapêutico , Fígado/imunologia , Fígado/metabolismo , Fígado/patologia , Masculino , Oligossacarídeos/efeitos adversos , Oligossacarídeos/uso terapêutico , Tamanho do Órgão , Prebióticos/efeitos adversos , Ratos Wistar , Aumento de PesoRESUMO
This study aimed to assess the effects of a yacon-based product (YBP) on constipation in adults, including the elderly. Forty-eight individuals were recruited and divided into equal intervention groups named the test and control groups. The YBP (test) and the control (maltodextrin) were dissolved in commercial orange juice. The volunteers for the YBP/test group consumed, on a daily basis, orange juice containing 10 g fructooligosaccharide (FOS)/inulin per day. The control group consumed, on a daily basis, orange juice containing 25 g of maltodextrin. The study had a span of 30 days. We evaluated the participants' frequency of evacuation, consistency of the feces, constipation score, abdominal symptoms (flatulence, pain, and abdominal strain), and effects upon the microbiota, pH, lactate, and short-chain fatty acids (SCFAs) of the feces. The study showed an increased number of evacuations after the consumption of the YBP as well as an improvement in the consistency of the feces and a reduction in the constipation score. After 30 days of intervention, the group that consumed the YBP showed higher counts of Bifidobacterium, lower Clostridium and enterobacteria counts, and lower fecal pH. In relation to SCFAs, no significant change was found after the intervention. However, the lactate concentration was higher in the test group when compared to the post-treatment control group. The YBP was effective in improving constipation symptoms; not only was its functional characteristic in reducing constipation symptoms evident but it also demonstrated usefulness as a potential therapy.
Assuntos
Asteraceae/química , Constipação Intestinal/dietoterapia , Defecação/efeitos dos fármacos , Intestinos/efeitos dos fármacos , Inulina/uso terapêutico , Oligossacarídeos/uso terapêutico , Prebióticos , Adulto , Bifidobacterium/crescimento & desenvolvimento , Clostridium/crescimento & desenvolvimento , Constipação Intestinal/complicações , Enterobacteriaceae/crescimento & desenvolvimento , Ácidos Graxos Voláteis/análise , Fezes/química , Fezes/microbiologia , Feminino , Humanos , Concentração de Íons de Hidrogênio , Intestinos/microbiologia , Inulina/farmacologia , Ácido Láctico/sangue , Masculino , Microbiota , Pessoa de Meia-Idade , Oligossacarídeos/farmacologia , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Adulto JovemRESUMO
AIMS: The consumption of prebiotics has been associated with improvement in the lipid profile. Thus, this review aims to describe the main mechanisms by which inulin-type fructans improve the lipid profile and thereby reduce the cardiovascular risk. DATA SYNTHESIS: Inulin-type fructans have been demonstrated to improve the lipid profile through a number of mechanisms. These mechanisms include: decrease in gene expression of hepatic enzymes responsible for de novo synthesis of lipids; increase of muscle lipoprotein lipase enzyme activity, enhancing the production of short-chain fatty acids; altered production of polyamines which increases the production of satiogenic peptide; altered blood glucose and insulinemia; increase of fecal excretion of bile salts and cholesterol and increase of the Bifidobacterium population. CONCLUSIONS: The consumption of inulin-type fructans enhances lipid profile. Generally, the mechanisms vary according to the physiologic state of the individual and the type of diet to which the inulin-type fructans are added. Thus, inulin may be used for the prevention and/or treatment of cardiovascular diseases.
Objetivos: El consumo de prebióticos ha sido asociado con el mejoramiento del perfil lipídico. Por tanto, esta revisión tiene como objetivo describir los principales mecanismos por los cuales fructanos tipo inulina, mejoran el perfil lipídico reduciendo el riesgo cardivascular. Síntesis de los datos: Los fructanos tipo inulina, han demostrado una mejora del perfil lipídico, a través de varios mecanismos, incluyendo: disminución de la expresión génica de las enzimas hepáticas responsables por la síntesis de novo de lípidos; aumento de la actividad enzimática del lipoproteína lipasa muscular; aumento de la producción de ácidos grasos de cadena corta; producción alterada de poliaminas que aumentan la producción del peptido Satiogen; alteración de la glicemia e insulinemia; aumento de la populación de Bifidobacterium y el incremento de la excreción fecal de las sales biliares y el colesterol. Conclusiones: El consumo de los fructanos tipo inulina mejora el perfil lipídico. Generalmente, los mecanismos varian de acuerdo com el estado fisiológico del individuo y el tipo de dieta, en la que son adicionados los fructanos tipo inulina. Por tanto, la inulina puede ser utilizada para la prevención y/o tratamiento de enfermedades cardiovasculares.
Assuntos
Frutanos/uso terapêutico , Inulina/uso terapêutico , Lipídeos/sangue , Animais , Dieta , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/prevenção & controle , MicrobiotaRESUMO
The incidence of colorectal cancer is growing worldwide. The characterization of compounds present in the human diet that can prevent the occurrence of colorectal tumors is vital. The oligosaccharide inulin is such a compound. The aim of this study was to evaluate the antigenotoxic, antimutagenic and anticarcinogenic effects of inulin in vivo. Our study is based on 3 assays that are widely used to evaluate chemoprevention (comet assay, micronucleus assay, and aberrant crypt focus assay) and tests 4 protocols of treatment with inulin (pre-treatment, simultaneous, post-treatment, and pre + continuous). Experiments were carried out in Swiss male mice of reproductive age. In order to induce DNA damage, we used the pro-carcinogenic agent 1,2-dimethylhydrazine. Inulin was administered orally at a concentration of 50 mg/kg body weight following the protocols mentioned above. Inulin was not administered to the control groups. Our data from the micronucleus assay reveal antimutagenic effects of inulin in all protocols. The percentage of inulin-induced damage reduction ranged from 47.25 to 141.75% across protocols. These data suggest that inulin could act through desmutagenic and bio-antimutagenic mechanisms. The anticarcinogenic activity (aberrant crypt focus assay) of inulin was observed in all protocols and the percentages of damage reduction ranged from 55.78 to 87.56% across protocols. Further tests, including human trials, will be necessary before this functional food can be proven to be effective in the prevention and treatment of colon cancer.
Assuntos
Focos de Criptas Aberrantes/prevenção & controle , Antineoplásicos/uso terapêutico , Inulina/uso terapêutico , Administração Oral , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacologia , Quimioprevenção , Neoplasias Colorretais/prevenção & controle , Dano ao DNA/efeitos dos fármacos , Inulina/administração & dosagem , Inulina/farmacologia , Masculino , Camundongos , Micronúcleos com Defeito Cromossômico/efeitos dos fármacosRESUMO
BACKGROUND: Obesity is a major public health problem in many poor countries where micronutrient deficiencies are prevalent. A partial meal replacement may be an effective strategy to decrease obesity and increase micronutrient intake in such populations. The objective was to evaluate the efficacy of a partial meal replacement with and without inulin on weight reduction, blood lipids and micronutrients intake in obese Mexican women. METHODS: In a randomized controlled clinical trial 144 women (18-50 y) with BMI ≥ 25 kg/m², were allocated into one of the following treatments during 3 months: 1) Two doses/d of a partial meal replacement (PMR), 2) Two doses/d of PMR with inulin (PMR + I) , 3) Two doses/d of 5 g of inulin (INU) and 4) Control group (CON). All groups received a low calorie diet (LCD). Weight, height, hip and waist circumference were measured every 2 weeks and body composition, lipids and glucose concentration and nutrient intake were assessed at baseline and after 3 months. RESULTS: All groups significantly reduced weight, BMI, waist and hip circumference. Differences between groups were only observed in BMI and weight adjusted changes: At 45 days PMR group lost more weight than INU and CON groups by 0.9 and 1.2Kg, respectively. At 60 days, PMR + I and PMR groups lost more weight than in INU by 0.7 and 1Kg, respectively. Subjects in PMR, PMR + I and INU significantly decreased triglycerides. Energy intake was reduced in all groups. Fiber intake increased in PMR + I and INU groups. Some minerals and vitamins intakes were higher in PMR and PMR + I compared with INU and CON groups. CONCLUSION: Inclusion of PMR with and without inulin to a LCD had no additional effect on weight reduction than a LCD alone but reduced triglycerides and improved intake of micronutrients during caloric restriction. PMR could be a good alternative for obese populations with micronutrient deficiencies.
Assuntos
Dieta Redutora/métodos , Suplementos Nutricionais , Hipertrigliceridemia/prevenção & controle , Inulina/uso terapêutico , Micronutrientes/administração & dosagem , Obesidade/dietoterapia , Sobrepeso/dietoterapia , Adolescente , Adulto , Aminoácidos Essenciais/administração & dosagem , Aminoácidos Essenciais/deficiência , Aminoácidos Essenciais/uso terapêutico , Índice de Massa Corporal , Países em Desenvolvimento , Dieta Redutora/efeitos adversos , Suplementos Nutricionais/análise , Feminino , Humanos , Hipertrigliceridemia/etiologia , Inulina/administração & dosagem , Estudos Longitudinais , México , Micronutrientes/deficiência , Micronutrientes/uso terapêutico , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/fisiopatologia , Sobrepeso/sangue , Sobrepeso/fisiopatologia , Pacientes Desistentes do Tratamento , Redução de Peso , Adulto JovemRESUMO
INTRODUCTION: Prebiotics positively affect gut microbiota composition, thus improving gut function. These properties may be useful for the treatment of constipation. OBJECTIVES: This study assessed the tolerance and effectiveness of a prebiotic inulin/partially hydrolyzed guar gum mixture (I-PHGG) for the treatment of constipation in females, as well as its influence on the composition of intestinal microbiota and production of short chain fatty acids. METHODS: Our study enrolled 60 constipated female health worker volunteers. Participants reported less than 3 bowel movements per week. Volunteers were randomized to treatment with prebiotic or placebo. Treatment consisted of 3 weeks supplementation with 15 g/d IPHGG (fiber group) or maltodextrin (placebo group). Abdominal discomfort, flatulence, stool consistency, and bowel movements were evaluated by a recorded daily questionnaire and a weekly interview. Changes in fecal bacterial population and short chain fatty acids were assessed by real-time PCR and gas chromatography, respectively. RESULTS: There was an increased frequency of weekly bowel movements and patient satisfaction in both the fiber and placebo groups with no significant differences. Total Clostridium sp significantly decreased in the fiber group (p = 0.046) and increased in the placebo group (p = 0.047). There were no changes in fecal short chain fatty acid profile. CONCLUSIONS: Consumption of I-PHGG produced clinical results comparable to placebo in constipated females, but had additional protective effects on gut microbiota by decreasing the amount of pathological bacteria of the Clostridium genera.
Assuntos
Constipação Intestinal/tratamento farmacológico , Galactanos/uso terapêutico , Inulina/uso terapêutico , Mananas/uso terapêutico , Metagenoma/fisiologia , Gomas Vegetais/uso terapêutico , Prebióticos , Adolescente , Adulto , Idoso , Constipação Intestinal/microbiologia , Suplementos Nutricionais , Método Duplo-Cego , Ácidos Graxos/metabolismo , Fezes/química , Fezes/microbiologia , Feminino , Galactanos/efeitos adversos , Humanos , Intestinos/microbiologia , Inulina/efeitos adversos , Mananas/efeitos adversos , Pessoa de Meia-Idade , Gomas Vegetais/efeitos adversos , Prebióticos/efeitos adversos , Resultado do Tratamento , Adulto JovemRESUMO
Considering the high frequency of anaemia due to Fe deficiency, it is important to evaluate the effects of prebiotics on the absorption of Fe. The aim of the present study was to evaluate the effects of high-performance (HP) inulin, oligofructose and synergy1 during recovery from anaemia in rats through the intestinal absorption of Fe, food intake, body growth, caecal pH and weight of the intestine. Wistar rats (n 47) were fed with rations of AIN93-G with no Fe to induce Fe deficiency anaemia. At 36 d of life, anaemic rats were divided into four groups: (1) the HP inulin group; (2) the synergy1 group; and (3) the oligofructose group, all with 100 g of the respective prebiotic per kg of ration; and (4) a control group, in which the prebiotic was replaced by maize starch. Then, 25 mg of elemental Fe/kg of ration was added to all rations to allow recovery from anaemia. The final values of Hb in the HP inulin, synergy1, oligofructose and control groups were, respectively: 98 (94-99); 83 (81-92); 100 (90-114); 77 (72-81) g/l, with a statistically significant difference (P ≤ 0·001) between the oligofructose and control groups and the HP inulin and control groups. The four groups had an increase in weight and body length and had similar consumption of rations. The intestinal weight and caecal pH were significantly different between the groups that consumed prebiotics and the control group. HP inulin and oligofructose increased the intestinal absorption of Fe in rats.
Assuntos
Anemia Ferropriva/dietoterapia , Absorção Intestinal , Mucosa Intestinal/metabolismo , Inulina/uso terapêutico , Ferro da Dieta/metabolismo , Oligossacarídeos/uso terapêutico , Prebióticos , Anemia Ferropriva/sangue , Anemia Ferropriva/metabolismo , Animais , Ceco/crescimento & desenvolvimento , Ceco/metabolismo , Colo/crescimento & desenvolvimento , Colo/metabolismo , Fezes/química , Conteúdo Gastrointestinal/química , Hematócrito , Hemoglobinas/análise , Concentração de Íons de Hidrogênio , Intestinos/crescimento & desenvolvimento , Ferro da Dieta/uso terapêutico , Masculino , Tamanho do Órgão , Ratos , Ratos Wistar , Aumento de PesoRESUMO
Constipation is a complex disorder, which affects an important part of the population and results in an increase of gastrointestinal symptoms and in lower stool frequency. The addition of soluble fibers (prebiotics) and probiotic in foodstuffs has been proposed as a useful tool to improve digestive wellbeing of affected individuals. The aim of this study was to evaluate the effect of the daily consumption of Minishot, a milk drink with prebiotics (inulin I polydextrose) and probiotics (Bifidobacterium lactis BB12), on the digestive comfort of healthy and constipated subjects. We conducted a randomized, controlled, double blind clinical trial in 33 healthy subjects and 64 constipated subjects (< 3 stools I week). Subjects underwent a one-week observation period followed by two periods of two weeks of consumption of Minishot or placebo, separated between them by a two-week washout period. The volunteers recorded daily in a table the presence and severity of distracters and digestive symptoms and the number and consistency of stools. Neither Minishot nor the placebo affected the digestive wellbeing or the stool frequency and consistency in the control subjects. In the constipated subjects, both consumption of Minishot and the placebo improved digestive comfort and stool frequency. However, compared with the placebo, Minishot significantly decreased the frequency of hard stools and the proportion of subjects emitting them, and increased the frequency of normal stools.
La constipación es un trastorno complejo que afecta una parte importante de la población. El consumo de prebióticos y probióticos ha sido propuesta como una herramienta para mejorar el bienestar digestivo de las personas afectadas. El objetivo del estudio fue evaluar el efecto del consumo diario de una bebida láctea con inulina/polidextrosa y Bifidobacterium lactis Bbl2, Minishot, sobre el bienestar digestivo de sujetos sanos o constipados. Se realizó un ensayo clínico randomizado, controlado y en doble ciego en 33 sujetos sanos y 64 sujetos constipados (< 3 deposiciones / semana). Después de una semana de observación, cada sujeto tuvo 2 periodos de 2 semanas de consumo de Minishot o del placebo, espaciados entre si por 2 semanas de reposo. Los voluntarios registraron diariamente la presencia e intensidad de síntomas digestivos y el número y consistencia de deposiciones. El consumo de Minishot no afecto en forma importante el bienestar digestivo de los sujetos sanos ni alteró la frecuencia y consistencia de sus deposiciones. En los sujetos constipados, tanto el consumo de Minishot como del placebo mejoraron el bienestar digestivo y la frecuencia de deposición. Comparado con el placebo, el consumo de Minishot disminuyó significativamente la frecuencia de deposiciones muy duras y la proporción de sujetos emitiéndolas, y aumento la frecuencia de deposiciones normales/blandas y la proporción de sujetos emitiéndolas.
Assuntos
Humanos , Feminino , Adulto , Bebidas , Bifidobacterium , Laticínios , Constipação Intestinal/terapia , Inulina/uso terapêutico , Probióticos/uso terapêutico , Defecação , Digestão , Método Duplo-CegoRESUMO
Las enfermedades gastrointestinales siguen siendo un problema de salud pública mundial. El avance de la ciencia muestra que cambios en el balance adecuado de la microflora intestinal (MI) juegan un papel crucial en la patogénesis. La evidencia apunta a que una manera de modular esta MI es a través del uso de oligosacáridos prebióticos, que estimulan el crecimiento de bacterias benéficas y que a la vez aumentan la resistencia a la invasión por patógenos. Estudios con animales indican que el consumo de carbohidratos prebióticos podría estar implicado en la prevención y tratamiento de diarreas. En infantes humanos sanos, los estudios revelan que el consumo de mezclas de prebióticas (galactooligosacáridos/fructooligosacáridos, inulina/galactooligosacáridos) disminuyen la incidencia de fiebre, de infecciones y de patógenos gastrointestinales. Lo anterior representa un gran potencial para los alimentos funcionales que los contienen, principalmente las fórmulas infantiles. Sin embargo, los estudios de prevención de diarreas mediante el suministro de prebióticos en personas con una microflora intestinal alterada no son concluyentes, sobre todo aquellos practicados en ancianos, personas con problemas crónicos de inflamación intestinal y personas con diarreas asociadas a la toma de antibióticos. Lo anterior nos indica la necesidad de estudios bioquímicos y microbiológicos más profundos en humanos de diferentes edades y condiciones de salud intestinal, a fin de determinar en que condiciones, los prebióticos tienen algún efecto sobre las infecciones.
Gastrointestinal disorders are still a main world public health problem. Scientific progress shows that and inadequate balance in intestinal microbiota (IM) plays a crucial role in its pathogenesis. Evidence indicates that one way to modulate the IM is through the use of prebiotics. These oligosaccharides stimulate the growth of benefic bacteria and increase the resistance to invading pathogens. Research using animals show that the consumption of prebiotics could be implicated in prevention and treatment of diarrhea. Studies in healthy infants also indicate that the consumption of prebiotic mixtures (galactooligosaccharides/ fructooligosaccharides, inulin/ galactooligosaccharides) decreases the incidence of fever, infections and pathogens. These results represent a great potential for functional foods that contain prebiotics, mainly the infant formulas. However, results of other clinical studies for prebiotics effects on diarrhea are not conclusive. Specially those studies that include patients with an altered IM (like the elderly), patients with chronic intestinal inflammation and with diarrhea associated to antibiotic treatments. There is a need for more biochemical and microbiological studies in humans at different ages and intestinal health conditions, in order to determine when prebiotics may effectively function on infections.
Assuntos
Humanos , Masculino , Feminino , Gastroenteropatias/prevenção & controle , Enteropatias/prevenção & controle , Controle de Infecções , Inulina/uso terapêutico , Oligossacarídeos/uso terapêuticoRESUMO
AIM: To evaluate the effect of a probiotic, Lactobacillus acidophilus LB (LB), or a synbiotic, Saccharomyces boulardii plus inulin (SbI), on Helicobacter pylori (Hp) colonization in children. SUBJECTS AND METHODS: A clinical trial was carried out in a school from a low socio-economic area of Santiago. Two hundred and fifty-four asymptomatic children (8.40+/-1.62 y) were screened for Hp by the (13)C-Urea Breath Test ((13)C-UBT). Hp-positive children were randomly distributed into three groups to receive either antibiotic treatment (lanzoprazole, clarythromycin and amoxicillin) for 8 d, or SbI or LB daily for 8 wk. A second (13)C-UBT was carried out at this time. Spontaneous clearance was evaluated in the same way in 81 infected, untreated children. The differences in the delta(13)CO(2) over baseline values before and after treatments (?DOB) were evaluated. RESULTS: 182 subjects (71.7%) were colonized by Hp, and 141 of them completed their treatment (22.5% dropout). Hp was eradicated in 66%, 12% and 6.5% of the children from the Ab, SbI and LB groups, respectively, while no spontaneous clearance was observed in the children without treatment. A moderate but significant difference in ?DOB was detected in children receiving living SbI (-6.31; 95% CI: -11.84 to -0.79), but not in those receiving LB (+0.70; 95% CI: -5.84 to +7.24). CONCLUSION: S. boulardii seems promising as an agent that interferes with Hp in colonized individuals. More studies are needed to confirm these results and to elucidate the mechanisms by which Sb inhibits Hp.